Massive Bio Facebook ad: “HER2-Mutant NSCLC Trials”

Ran for 54 days, from August 13 to October 6, 2026, the last day Crush saw it.
Run by Massive Bio on Facebook. Crush is not the advertiser and does not verify its claims. See this ad in Meta's Ad Library(opens in a new tab)
Make your own version of this ad
Crush makes it, launches it in your own Meta ad account, scales the winners and pauses the losers.
About this ad
- Meta Ad Library ID
- 2197162194165192
- Platforms
- Facebook, Instagram, Audience Network, Messenger and Threads
- Relaunches
- 0
Ad text
Patients with HER2-mutant, treatment-naïve non-squamous NSCLC may qualify for a first-line clinical trial. Identify and refer eligible cases.
Where the ad sends people
massivebio.com
HER2-Mutant NSCLC Trials
HER2 mutation | Stage III–IV | No prior systemic therapy
Learn more: massivebio.com(opens in a new tab)










